Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma

Two tyrosine kinase inhibitors, lenvatinib and sorafenib, are available systemic therapies for patients with metastatic differentiated thyroid carcinoma. However, the treatment options for carcinoma refractory to both lenvatinib and sorafenib are limited. Here, we present a case of metastatic papill...

Descripción completa

Detalles Bibliográficos
Autores principales: Takinami, Masaki, Yokota, Tomoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265699/
https://www.ncbi.nlm.nih.gov/pubmed/32518548
http://dx.doi.org/10.1159/000507344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265699/
https://www.ncbi.nlm.nih.gov/pubmed/32518548
http://dx.doi.org/10.1159/000507344

Ejemplares similares